Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May:116:102558.
doi: 10.1016/j.ctrv.2023.102558. Epub 2023 Apr 9.

Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification

Mimma Rizzo  1 , Anna Caliò  2 , Matteo Brunelli  2 , Gaetano Pezzicoli  3 , Carlo Ganini  3 , Guido Martignoni  4 , Porta Camillo  5
Affiliations
Review

Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification

Mimma Rizzo et al. Cancer Treat Rev. 2023 May.

Abstract

The new WHO classification of urogenital tumours published in 2022, contains significant revisions upon the previous 2016 version regarding Renal Cell Carcinoma (RCC). While the most common histotype remains almost untouched, some of the main novelties concerns papillary RCC and oncocytic neoplasms. The main change is the introduction of a new category of molecularly-defined RCC, which includes TFE3-rearranged RCC, TFEB-rearranged, and TFEB-amplified RCC, FH-deficient RCC, SDH-deficient RCC, ALK-rearranged RCC, ELOC (formerly TCEB1)-mutated RCC, SMARCB1 (INI1)-deficient RCC. In this paper we analyze the current knowledge on emerging entities and molecularly-defined RCC to assess whether the current pathological classification offers the oncologist the possibility of selecting more specific and personalized treatments, from both those currently available, as well as those that will soon be available.

Keywords: 2022 WHO RCC classification; Clinical implications; Molecular definition; Renal cell carcinoma; Targeted therapies.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

MeSH terms

LinkOut - more resources